Skip to main content

Table 2 COS treatment and embryo culture

From: The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles

Variables uFSH
(n = 764)
rFSH-alfa
(n = 314)
P
Gn total dose (IU) 2334.5 ± 687.3 1912.3 ± 625.1 < 0.001
Oocytes retrieved 10.0 (6.8–14.0) 13.0 (8.0–17.0) < 0.001
2PN oocytes 5.0 (3.0–8.0) 7.0 (4.0–11.0) < 0.001
Transferrable embryos 4.0 (2.0–6.0) 5.0 (3.0–8.0) < 0.001
High-quality embryos 3.0 (1.0–5.0) 4.0 (1.0–6.0) < 0.001
OHSS 36 (4.7%) 22 (7.0%) 0.129
IVF/ICSI    0.014
 ICSI 118 (15.4%) 68 (21.7%)  
 IVF 646 (84.6%) 246 (78.3%)  
Number of embryo transfer cycles    < 0.001
 0 141 (18.5%) 32 (10.2%)  
 1 408 (53.4%) 154 (49.0%)  
 2 152 (19.9%) 90 (28.7%)  
 3 57 (7.5%) 25 (8.0%)  
 4 6 (0.8%) 10 (3.2%)  
 5 0 (0.0%) 3 (1.0%)  
  1. COS controlled ovarian stimulation; OHSS ovarian hyperstimulation syndrome; IVF in vitro fertilization; ICSI intracytoplasmic sperm injection; FSH follicle-stimulating hormone